These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 12733224)
1. Botanical drugs: a future for herbal medicines. Li W J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224 [No Abstract] [Full Text] [Related]
2. Botanical medicines--the need for new regulations. Marcus DM; Grollman AP N Engl J Med; 2002 Dec; 347(25):2073-6. PubMed ID: 12490692 [No Abstract] [Full Text] [Related]
3. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
4. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
6. [Herbal drugs: from traditional use to regulation]. Federici E; Multari G; Gallo FR; Palazzino G Ann Ist Super Sanita; 2005; 41(1):49-54. PubMed ID: 16037650 [TBL] [Abstract][Full Text] [Related]
7. Technology: drug and device export reform. Betz R J Healthc Resour Manag; 1995 Oct; 13(10):30, 33. PubMed ID: 10151686 [No Abstract] [Full Text] [Related]
8. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]
9. Dosing botanical medicines. Yarnell E J Herb Pharmacother; 2005; 5(1):73-8. PubMed ID: 16093237 [No Abstract] [Full Text] [Related]
10. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
11. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: FDA oversight. Chaps NA Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718 [No Abstract] [Full Text] [Related]
18. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]